Covira Surgical

03/02/2023

Covira Announces Appointment of Brian Yoor as New Chairman of its Board of Directors

/PRNewswire/ -- Covira, a Chicago-area biotech company developing novel therapeutic agents to modulate the gut microbiome to prevent diseases, announces the...

10/06/2022

See below Covira's first company issued press release...

/PRNewswire/ -- Covira, a Chicago-area based microbiome-focused biotech company focused on developing novel therapeutic agents that modulate the gut microbiome...

04/19/2022

GOING WITH A GUT FEELING
By Lake County Partners, Date: April 19, 2022

click the link below to read the full article...
https://www.lakecountypartners.com/going-with-a-gut-feeling/

THE CASE OF COVIRA
Covira is a biotech company spun out from the University of Chicago that develops drugs to modulate the gut microbiome. Its lead asset is focused on the prevention of post-surgical infections. Covira is productively using its time at Helix 51 to prepare for its next capital raise of $15 million needed to complete Phase 1 and Phase 2 of human clinical trials. The company projects that the FDA approval process could take 4 – 5 years to complete.

“We are really at the cutting-edge of microbiome research, and our work stands to prevent both the incidence and progression of post-surgical infection and its subsequent development of disability and mortality. Our team is led by Dr. John Alverdy, MD, a world authority in this field whose knowledge led us to be named one of the top twenty most innovative companies by Business Worldwide Magazine,” said Covira Surgical CEO Peter Farmakis. “We chose Helix 51 because we know that Lake County is the heart of the nation’s life science corridor. Here, we will be able to find the additional talent and investors that we need to successfully achieve Covira’s growth objectives.”
..to read the full article click the link below
https://www.lakecountypartners.com/going-with-a-gut-feeling/

When the Chicago Tribune recently asked Congressman Brad Schneider to comment on the wave of biotech startups growing at Rosalind Franklin University’s Helix 51 incubator, he called Lake County “the home of the nation’s life ... Read More

04/19/2022

Covira Achieves 4 Milestones In April (MTD)

1. Covira Signs Agreement with Contract Development Manufacturing Organization (CDMO) Bright Path Labs to Produce lead asset CS-0003. (April 2022)
2. Covira establishes an impressive Business Advisory Board, the first members include biotech industry leaders Jeff Schaffnit and Jason Slotnik. (April 2022)
3. Covira’s Founder & Chief Scientific Officer (Dr. John Alverdy) presents abstract titled "A Novel Non-Antibiotic Gut-Directed Strategy to Prevent Surgical Site Infections" at the American Surgical Association's 142nd Annual Meeting. (April 2022)
4. Covira submits $2.3M STTR Fast-Track application “A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection” to the NIH SEED Fund. (April 2022)

*To See Additional Milestones Achieved visit Covira's website "News & Events"

Reminder Investment Opportunity Closes April 27th

Post-Surgical Infection Prevention

04/11/2022

Covira Investors & Followers:

Live Q&A Session

Join Dr. John Alverdy, Founder & Chief Scientific Officer and Peter Farmakis, CEO for Covira during the upcoming Live Question & Answer Session April 14th at 1:00pm CST Opt In Here to attend.
https://us06web.zoom.us/webinar/register/WN_Tsg76nWLRuygXj2G9GvMpw

04/03/2022

Covira submits $2.3M STTR Fast-Track application “A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection” to the NIH SEED Fund. This 133 page grant application was submitted on 4.2.22. A special thank you to all of Covira's team member's, Covira's business partners, and our consulting partner Dana from Eva Garland Consulting for all your efforts over the last 3-months to pull together this extremely impressive proposal.

The NIH Fast-Track application process expedites award decisions and funding of SBIR and STTR Phase II applications for scientifically meritorious projects that have a high potential for commercialization.

If awarded this $2.3M will be incremental non-dilutive funding - meaning this funding would not dilute Covira's investors.

https://lnkd.in/eyKbBk5

Kind Regards,
Peter Farmakis, CEO Covira

Post-Surgical Infection Prevention

03/29/2022

Covira Is One Of The Most Funded Companies On StartEngine

Investment Opportunities On StartEngine "Currently In Process" - "All Industries" - "Most Funded"
Covira is Ranked in the Top 15% of Most Funded Companies on StartEngine

Currently In Process "Most Funded" By Industry
#1 Ranking in Biotechnology
#1 Ranking in Pharmaceutical
#2 Ranking in Health Tech

*Covira Investment Opportunity Closes in 30 days

To take advantage of this offering, click below to invest now!

Post-Surgical Infection Prevention

03/18/2022

Covira's Capital Raise Continues To Accelerate (40 Days Remaining)

Dear Investors & Followers - Covira's capital raise continues to accelerate, as you can see from the graph below. March (MTD) is already the second largest month (total monthly dollars invested), and March is on track to be the largest month of this offering.

Why is this? The primary reason for the continued acceleration is that our investors are making larger investments - taking advantage of the larger investment bonus share rewards.

-Tier 1 Invest $1,000+, you will receive 5% bonus shares
-Tier 2 Invest $5,000+, you will receive 10% bonus shares
-Tier 3 Invest $10,000+, you will receive 15% bonus shares
-Tier 4 Invest $25,000+, you will receive 20% bonus shares
-Tier 5 Invest $100,000+, you will receive 25% bonus shares

We now have 422 Investors and a total of 843 Investors+Followers following our $1.0M Capital Raise here on StartEngine (reminder after raising $8.1M of non-dilutive funding, this $1.0M offering is Covira's first dilutive funding effort).

*If you are considering an investment or a second/third investment in Covira, now is the time (40-days remaining).
-Click on the link below to complete your investment ($250 minimum): https://www.startengine.com/covira-surgical

Kind Regards,
Peter Farmakis, CEO Covira

03/14/2022

Important Updates (including 45-day notice) from Covira's CEO

To Covira's Investors & Followers,

The opportunity to invest in Covira is closing in 45 days. To date Covira Surgical (Biotech) has secured more than 60% of the current $1.0M offering https://lnkd.in/eyKbBk5. Covira's investment opportunity will be getting a lot of additional attention over the next 6-weeks, please see important updates below...

1. March 22-24th Covira will be attending "Redefining Early Stage Investments (RESI) Digital RESI - Connecting Early Stage Products with Capital & Channel Partners"
1a. Life science and healthcare fundraising CEOs gain access to investors and strategic partners actively seeking opportunities that match their product set and stage of development through a match-based partnering system, pitch session opportunities, and industry expert panels.

2. April 7th Dr. John Alverdy, Founder & Chief Scientific Officer (Covira) will be presenting at the American Surgical Association's (The oldest surgical association in the United States) - 142nd Annual Meeting in Chicago, IL.
2a. A Novel Non-Antibiotic Gut-Directed Strategy to Prevent Surgical Site Infections https://lnkd.in/eyKbBk5

3. The opportunity to invest in Covira via the $1.0M Offering https://lnkd.in/eyKbBk5 is scheduled to close by April 27th
3a. Please note once the Offering Max of $1.07M is achieved Covira can no longer accept investment

4. This month Keiretsu Forum Midwest will be completing their due diligence final report regarding the Covira Surgical (Biotech) investment opportunity. This final report will be provided to the Angel Investors/Members of Keiretsu. Keiretsu Form Midwest is a part of Keiretsu Forum which includes 50+ chapters and over 3,000 angel investors on FOUR continents. *A special thank you to the Team from Keiretsu and Scott Hales (Covira) who put in significant time and effort to complete this due diligence effort and final report.
4a. Key Due Diligence Team Participants (the “Team”):
- Patrick Hennessey - Coordinator/Lead, Marketing/Competition, and Site Visit
- Adam Elhofy - Finance
- Valerie (Val) Adegbite-Calloway - Science/Technology
- Park Burrets - Reference ChecksDocumentation Checklist:
- A review of the primary corporate documents and contracts and deal documents was conducted by Wood & Lamping LLP, and is detailed in this report entitled “Review of Corporate and Deal Documents.” The documents reviewed are listed in the checklist included.


Kind Regards,
Peter Farmakis, CEO Covira Surgical (Biotech)

Post-Surgical Infection Prevention

03/01/2022

$500,000 Milestone
After raising $8.1M of non-dilutive funding, we (Covira) launched our first dilutive funding effort via a $1.0M Pre-Seed Reg CF Offering here on StartEngine. This investment opportunity (for friends, family and person contacts) is more than 50% funded and will be closing on or before April 27th. Over the next 60-days (March-April) we will be actively engaging the larger institutional investors regarding Covira’s investment opportunity.

To purchase shares of Covira at $1.00 per share, see steps below.

1. Click here; https://www.startengine.com/covira-surgical
2. Then click on invest now (green rectangle box)
3. That will take you to the form to complete, should take 5-10 minutes to complete

*To note there are additional bonus incentive shares for larger investment amounts, as an example…

- If you invest $5,000, you receive an additional 10% bonus shares = 5,500 shares, each share is $1.00 with bonus shares your post investment value is $5,500
- If you invest $10,000, you receive an additional 15% bonus shares = 11,500 shares, each share is $1.00 with bonus shares your post investment value is $11,500
- If you invest $25,000, you receive an additional 20% bonus shares = 30,000 shares, each share is $1.00 with bonus shares your post investment value is $30,000

02/08/2022

Post-Surgical Infection Prevention